Comments
Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the USFDA to market Nystatin Topical Powder USP, 100,000 units per gram.
The drug will be produced at Nesher’s facility located at St Louis, US. Nystatin is an anti-fungal drug used to treat skin infections caused by yeast, a company statement said.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.